ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

THE PREVALENCE OF EXTRACTABLE NUCLEAR ANTIGEN ANTIBODIES IN THE GENERAL POPULATION OF PAKISTAN A RETROSPECTIVE STUDY

AUTHORS:

Dr Muhammad Zubair Dr Fauzia Khan Dr Shah Alam

ABSTRACT:

Abstract: OBJECTIVE: To determine the prevalence of extractable nuclear antigen antibodies in general population of Pakistan Study Design: Retrospective study Place and Duration: Department of chemical pathology and immunology Chughtai Lab Lahore from January 2018 to December 2018. Patients and Methods: Data was retrieved from Nexus pro, laboratory information management system installed at Chughtai lab Lahore after approval from research ethics committee. Data of twenty five (25) anti ENA antibodies of 1268 subjects were collected and entered in SPSS version 23.0 for analysis. The samples of these patient were analyzed on D-Tek blue dot driver instrument which is based on the principle of immunoblot. RESULTS. The mean age of the study population was 38.08±15.38 years. Females patients were 675(67%) which were higher than males 325(32%). The frequency of all twenty five antibodies were determined which are as follows: Anti Nucleosome IgG56(5.6%), Anti dsDNA IgG76(7/6%), Anti Histones72(7.2%), Anti Sm IgG63(6.3%). Anti-Ribosome PO IgG15(1.5%), Anti PCNA IgG, 52(5.2%), Anti RNP IgG 68kD/A/C88(8.8%), Anti Sm/RNP IgG124(12.4%), Anti SSA(Ro) IgG 60kD173(17.3%), SSA/Ro 52kD117(11.7%), Anti SSB53(5.3%), Anti ScI-70 IgG27(2.7%), Anti CENP/A-B IgG25(2.5%), Anti Ku IgG30(3%), Anti PM/Scl IgG41(4.1%), ANTISPR I gG 54 29(2.9%), Anti Mi -2 IgG 3(0.3%), Anti Sp100 IgG 52(5.2%),Anti gp210 IgG 44(4.4%), Anti M2 Recombinent60(6%), Anti M2Native 46(4.6%), Anti F-actin IGG 25(2.5%), Anti Jo 1 IGG 15(1.5%), Anti Pl 7 IGG9(0.9%), Anti PL 12 IGG 9(0.9%). CONCLUSION: Most common extractable nuclear antigen antibody in this study samples were found to be Anti SSA(Ro)lg G 60kD with frequency of 173(17.3%). Keywords: Antigen, Antibodies, Anti Nucleosome, Anti Histones

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.